-
Mashup Score: 1BrainStorm to Announce Third Quarter 2023 Financial Results and Provide a Corporate Update - 1 year(s) ago
NEW YORK, Nov. 7, 2023 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call on Tuesday, November 14 th at 8:30 a.m. Eastern Time to discuss its financial results for the third quarter ended September 30, 2023 and provide a corporate update. BrainStorm’s President and Chief Executive Officer, Chaim Lebovits, and Co-Chief Executive Officer, Stacy Lindborg, PhD, will
Source: www.streetinsider.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 8Seelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023 - 1 year(s) ago
-SLS-005 induces autophagy to reduce mutant protein aggregates, and is currently being studied in Alzheimer’s disease, Huntington’s disease, Amyotrophic Lateral Sclerosis and Spinocerebellar…
Source: www.streetinsider.comCategories: General Medicine News, Rare DiseaseTweet-
Dear People w Alzheimer's, Huntington's, Spinocerebellar ataxia, If they promise you OLE, be sure to get it in writing! Seelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023 https://t.co/pB6eW7kuaU via @Street_Insider
-
-
Mashup Score: 17Merck (MRK) KEYTRUDA Met Primary Endpoint of DFS in Certain Patients With MIUC After Surgery - 1 year(s) ago
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, met one of its dual primary endpoints of disease-free survival (DFS) for the adjuvant treatment of patients with localized muscle-invasive urothelial carcinoma (MIUC) and locally advanced urothelial carcinoma versus observation. At a pre-specified interim analysis review conducted by an independent Data Monitoring
Source: www.streetinsider.comCategories: Hem/Oncs, Latest HeadlinesTweet-
JUST IN: via @Street_Insider AMBASSADOR trial: Pembro extends DFS in high-risk urothelial/bladder cancer, an @ALLIANCE_org @theNCI study ! @apolo_andrea @DrRosenbergMSK @MattGalsky @OncoAlert https://t.co/GOAZeGQP8D https://t.co/vZmFKQWAxr
-
Merck (MRK) KEYTRUDA Met Primary Endpoint of DFS in Certain Patients With MIUC After Surgery - AMBASSADOR trial https://t.co/tftGcbJibp
-
-
Mashup Score: 3Newly Released Data on Certified PAs Working in Emergency Medicine and Urgent Care Demonstrate Their Significant Contributions to Patient Care - 3 year(s) ago
, /PRNewswire/ — The National Commission on Certification of Physician Assistants (NCCPA), in collaboration with the Society of Emergency Medicine PAs (SEMPA) have published the PAs Practicing in Emergency Medicine and Urgent Care: 2021 Survey Results. Over 16,000 Certified PAs practice in Emergency Medicine and Urgent Care, and this report comprises the most comprehensive source of…
Source: www.streetinsider.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
Newly Released Data on #CertifiedPAs Working in #EmergencyMedicine and Urgent Care Demonstrate Their Significant Contributions to Patient Care @Street_Insider https://t.co/v0bgOIyhHq
-
-
Mashup Score: 1Celularity (CELU) Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 - 3 year(s) ago
Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its investigational natural killer (NK) cell therapy, CYNK-101, for treatment of gastric/gastroesophageal junction cancer. CYNK-101 is…
Source: www.streetinsider.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
RT @DrBobHariri: Celularity (CELU) Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 https://t.co/XJhrerjWIa
-
-
Mashup Score: 7Seagen (SGEN) Announces ADCETRIS Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma - 3 year(s) ago
Seagen Inc. (Nasdaq: SGEN) today announced that the phase 3 ECHELON-1 clinical trial demonstrated a statistically significant improvement in overall survival (OS) (p=0.009) in patients with advanced classical Hodgkin lymphoma (cHL) following treatment with ADCETRIS (brentuximab vedotin) in combination with chemotherapy. With approximately six years median follow up,…
Source: www.streetinsider.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @DrAEvens: https://t.co/3YskOXG2xo 👀👀👀 #Hodgkin #Lymphoma https://t.co/1rhad65afm
-
-
Mashup Score: 2Seagen (SGEN) Announces ADCETRIS Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma - 3 year(s) ago
Seagen Inc. (Nasdaq: SGEN) today announced that the phase 3 ECHELON-1 clinical trial demonstrated a statistically significant improvement in overall survival (OS) (p=0.009) in patients with advanced classical Hodgkin lymphoma (cHL) following treatment with ADCETRIS (brentuximab vedotin) in combination with chemotherapy. With approximately six years median follow up,…
Source: www.streetinsider.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @DrAEvens: https://t.co/3YskOXG2xo 👀👀👀 #Hodgkin #Lymphoma https://t.co/1rhad65afm
-
-
Mashup Score: 12Nanox (NNOX) Signs MSaaS Agreement for the Deployment of 1,000 Nanox Systems in Nigeria - 4 year(s) ago
NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging company, enters the West African market, signing an exclusive distribution deal with EiLEENO Pharma to deploy Nanox’s medical imaging services in Nigeria.The Nanox System is composed of the Nanox.ARC, a medical imaging system incorporating a novel digital X-ray source, and the Nanox.CLOUD, a companion…
Source: www.streetinsider.comCategories: Future of Medicine, Latest HeadlinesTweet-
Nanox Signs MSaaS Agreement for the Deployment of 1,000 Nanox Systems in Nigeria. @nanox_vision $NNOX #digitalhealth #Nigeria #radiology https://t.co/vqOUHJ7sfN
-
-
Mashup Score: 9Merck (MRK) Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival in Patients With High-Risk Early-Stage TNBC - 4 year(s) ago
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the pivotal neoadjuvant/adjuvant Phase 3 KEYNOTE-522 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy as pre-operative (neoadjuvant) treatment and then continuing as a single agent (adjuvant) treatment after surgery….
Source: www.streetinsider.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Phase 3 KEYNOTE-522 trial with pembrolizumab and chemotherapy met dual primary endpoint of higher pCR and event free survival for patients with localized high-risk TNBC. Full data to be presented at upcoming meeting. #bcsm @OncoAlert https://t.co/4kw1AcdMUY
-
-
Mashup Score: 4
KEYTRUDA Is the First Anti-PD-1 Therapy Approved in Combination With Trastuzumab and Chemotherapy for the First-line Treatment of These Patients KENILWORTH, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with…
Source: www.streetinsider.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Hear ye hear ye! FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal cancer https://t.co/Ds9Wkeyr5A
-
$bcli https://t.co/Gk4lVzZkc7